Evidence map›Paper›PMID 38564716›Full record

ArticlemSystems2024

Oxytetracycline hyper-production through targeted genome reduction of

Alen Pšeničnik, Lucija Slemc, Martina Avbelj, Miha Tome, Martin Šala, Paul Herron, Maksym Shmatkov, Marko Petek, Špela Baebler, Peter Mrak and 4 more

Open access · goldAbstract read
In one paragraph

Article in mSystems, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
3.1field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Promising non-model microbial cell factories obtained by genome reduction.Frontiers in bioengineering and biotechnology · 2024
    Review
  6. Modulating Complex Secondary Metabolism inFood technology and biotechnology
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 4 countries.

Alen PšeničnikChair of Biotechnology, Microbiology and Food Safety, University of Ljubljana Biotechnical Faculty, Ljubljana, Slovenia.ORCID 0000-0001-5375-2220
Lucija SlemcChair of Biotechnology, Microbiology and Food Safety, University of Ljubljana Biotechnical Faculty, Ljubljana, Slovenia.
Martina AvbeljChair of Biotechnology, Microbiology and Food Safety, University of Ljubljana Biotechnical Faculty, Ljubljana, Slovenia.
Miha TomeChair of Biotechnology, Microbiology and Food Safety, University of Ljubljana Biotechnical Faculty, Ljubljana, Slovenia.ORCID 0000-0001-7729-7381
Martin ŠalaNational Institute of Chemistry, Ljubljana, Slovenia.
Paul HerronStrathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, United Kingdom.ORCID 0000-0003-3431-1803
Maksym ShmatkovFaculty of Food Technology and Biotechnology, University of Zagreb, Zagreb, Croatia.
Marko PetekDepartment of Biotechnology and Systems Biology, National Institute of Biology, Ljubljana, Slovenia.ORCID 0000-0003-3644-7827
Špela BaeblerDepartment of Biotechnology and Systems Biology, National Institute of Biology, Ljubljana, Slovenia.ORCID 0000-0003-4776-7164
Peter MrakAntiinfectives, Sandoz, Mengeš, Slovenia.
Daslav HranueliFaculty of Food Technology and Biotechnology, University of Zagreb, Zagreb, Croatia.
Antonio StarčevićFaculty of Food Technology and Biotechnology, University of Zagreb, Zagreb, Croatia.
Iain S HunterStrathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, United Kingdom.
Hrvoje PetkovićChair of Biotechnology, Microbiology and Food Safety, University of Ljubljana Biotechnical Faculty, Ljubljana, Slovenia.ORCID 0000-0003-1377-9845
University of Ljubljana · SIUniversity of Zagreb · HRNational Institute of Biology · SIUniversity of Strathclyde · GBNational Institute of Chemistry · SI

Funding

Javna Agencija za Raziskovalno Dejavnost RS (ARRS) 53621Javna Agencija za Raziskovalno Dejavnost RS (ARRS) P1-0034Javna Agencija za Raziskovalno Dejavnost RS (ARRS) P4-0116Javna Agencija za Raziskovalno Dejavnost RS (ARRS) P4-0165
6 · The paper itself

Abstract

Most biosynthetic gene clusters (BGC) encoding the synthesis of important microbial secondary metabolites, such as antibiotics, are either silent or poorly expressed; therefore, to ensure a strong pipeline of novel antibiotics, there is a need to develop rapid and efficient strain development approaches. This study uses comparative genome analysis to instruct rational strain improvement, using

Indexed as

Anti-Bacterial AgentsGenome, BacterialMultigene FamilyOxytetracyclineStreptomyces rimosusStreptomycesAnti-Bacterial AgentsOxytetracyclineantibiotic biosynthesiscryptic metabolitesgenome reductionoxytetracycline

Identifiers

PMID38564716
PMCPMC11097637
OpenAlexW4393404564

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.